PeptideHelper.org
Your evidence-based peptide reference
Research reference only. Not medical advice. Most compounds are not FDA-approved. Consult a qualified clinician before any human use.

Weight Loss & Metabolic

Cagrilintide + Semaglutide

CagriSema

Classification: Amylin + GLP-1 combination

Mechanism: Dual amylin + GLP-1 receptor agonism

Benefits: Weight loss ~15-22% Phase 2/3; enhanced appetite control

Evidence tier: Phase 3 · Availability: Investigational

Primary sources

  1. Garvey WT et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med 2025. PMID 40544433
  2. Frias JP et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes. Lancet 2023. PMID 37364590

Loading interactive view…